Drug
Tirabrutinib clinical trials
Also written ONO-4059 and GS-4059.
Keep track of what changes. Save the tirabrutinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 1
Ono Pharmaceutical Co., Ltd. (5) · Gilead Sciences (5) · Kyorin University (1)
Often tested with
Tested in the same studies.
Rituximab (1) · Methotrexate (1) · Procarbazine (1) · Vincristine (1) · Lanraplenib (1) · GLPG0634 (1)
Studies
Open first, then newest update. How each study uses tirabrutinib is read from its arms, and is right about nine times in ten.
Testing it · 11
- IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)RecruitingPhase 3Ono Pharmaceutical Co., Ltd.NCT07104032Written as Tirabrutinib
- Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104)RecruitingPhase 2Kyorin UniversityNCT06940791Written as Tirabrutinib
- Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSLActive, not recruitingPhase 1Ono Pharmaceutical Co., Ltd.NCT06541665Written as ONO-4059
- ONO-4059 Study in Patients With Steroid-resistant PemphigusActive, not recruitingPhase 3Ono Pharmaceutical Co., Ltd.NCT06696716Written as ONO-4059
- A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy ParticipantsCompletedPhase 1Ono Pharmaceutical Co., Ltd.NCT07198087Written as Tirabrutinib
- Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)Active, not recruitingPhase 2Ono Pharmaceutical Co., Ltd.NCT04947319Written as Tirabrutinib
- Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell MalignanciesCompletedPhase 1Gilead SciencesNCT02457559Written as Tirabrutinib
- Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous UrticariaWithdrawnPhase 2Gilead SciencesNCT04827589Written as Tirabrutinib
- Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLLCompletedPhase 1Gilead SciencesNCT01659255Written as Tirabrutinib
- Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's SyndromeCompletedPhase 2Gilead SciencesNCT03100942Written as Tirabrutinib
- Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)CompletedPhase 1Gilead SciencesNCT02626026Written as Tirabrutinib
Given in every arm · 3 — tirabrutinib is usual care beside what is tested
- Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell MalignanciesTerminatedPhase 1Gilead SciencesNCT02457598Written as Tirabrutinib
- Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)CompletedPhase 2Gilead SciencesNCT02968563Written as Tirabrutinib
- Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)CompletedPhase 2Gilead SciencesNCT02983617Written as Tirabrutinib
Codes
What other systems call tirabrutinib · ClinicalTrials.gg INT000477
- MeSH (NLM) C000608238tirabrutinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) LXG44NDL2TTIRABRUTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27283239tirabrutinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C102876TirabrutinibOne source FDA
- DrugBank DB15227One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000608238 | tirabrutinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | LXG44NDL2T | TIRABRUTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27283239 | tirabrutinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C102876 | Tirabrutinib | One source FDA |
| DrugBank | DB15227 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.